Kornimate/medical-research-clean huggingface dataset:
citalopram for cocaine dependence

Conditions: Cocaine Dependence

Summary: this is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine dependence. using a double-blind, randomized controlled design, eligible cocaine dependent patients will be assigned equally to one of three medication conditions: placebo or the selective serotonin re-uptake inhibitor (ssri) agent, citalopram at either 20 mg per day or 40 mg per day. it is hypothesized that citalopram will reduce cocaine use and increase periods of sustained abstinence substantially more than placebo. performance on a set of behavioral tasks of impulsivity will be analyzed as potential predictors of treatment response.


Eligibility criteria:
inclusion criteria: * between 18 and 60 years of age * meet diagnostic and statistical manual 4 (dsm-iv) criteria for current cocaine dependence * be in acceptable health on the basis of interview, medical history and physical exam * able to provide the names of at least 2 persons who can generally locate their whereabouts. exclusion criteria: * diagnosis of any psychoactive substance dependence other than cocaine, marijuana, or nicotine * have a psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe * medical conditions contraindicating citalopram pharmacotherapy * taking medications known to have significant drug interactions with the study medication * pregnant or nursing for female patients * having plans to leave the immediate geographical area within 3 months

Keywords: cocaine citalopram treatment serotonin
delta describe: the french collaborative project

Conditions: Hepatitis D

Summary: our global objective is to draw up a photograph of hdv patients over one year in metropolitan france and identify the barriers of screening and care. the investigator suspects a mismatch between hbv and hdv screening, the first step for specialized care pathway in metropolitan france.

hepatitis delta virus (hdv) infection is a significant public health disease causing up to 18% of cirrhosis and 20% of hepatocellular carcinoma (hcc) and new therapeutic options are now available. in france, very few epidemiological studies, mainly focused on specific pre-selected hospital populations, are available. there is a crucial need for data in terms of delta knowledge, suitability of screening, type of prescribers and treatment access. the investigator proposes a retrospective study in order to describe the number of hdv tests (anti-hdv and hdv rna) performed in metropolitan france and compare it to the potentially expected one, estimated from the number of hbv screening tests performed in one year, from 2016 to 2020. the investigator will also evaluate the number of hcv and hiv screening tests prescribed over the same period and the hdv pcr techniques used. this study will be based on one hand on data from the french health insurance (first step) and on the other hand on data from private and hospital laboratories (second step). the second step will allow to identify the prescriber of the delta tests and the hdv positive patients and precise their profile and their medical care. after an initial analysis of the results, the investigator will propose solutions to the barriers encountered and adapted to the identified targets.

Eligibility criteria:
inclusion criteria: * \>18 years at the second step * hdv rna positive patients identified at the second step * patients non opposed to the collection of their data exclusion criteria: * opposition expressed by the patients for the collection of their data

Keywords: hbs ag delta hepatitis screening reflex testing
a study of ap-cd/ld in fluctuating parkinson's disease patients who completed in 11 004

Conditions: Parkinson's Disease

Summary: the purpose of this study is to allow evaluation of long-term clinical effect and safety outcome of treatment with ap-cd/ld, as well as to allow patients to benefit from extended treatment duration with ap-cd/ld after they have successfully completed the phase 3 core study in 11 004 ('core study', a phase iii, multicenter, randomized, double-blind, double-dummy, active-controlled phase 3 study to assess the safety and efficacy of ap cd/ld versus ir cd/ld in fluctuating pd patients).

this will be a multi-center, global, open-label study in adult suffering from fluctuating parkinson's disease subjects who have successfully completed the core study in 11 004. after signing informed consent and meeting inclusion/exclusion criteria, eligible subjects will be enrolled into a 12-month open-label extension and receive the ap-cd/ld as needed. efficacy and safety will be assessed throughout the study period.

Eligibility criteria:
inclusion criteria: 1. subjects who successfully completed the core study in 11 004 and, in the opinion of the investigator, would benefit from long-term treatment with ap-cd/ld 2. continue to carry the diagnosis of parkinson's disease consistent with uk brain bank criteria 3. has a good response to levodopa in the opinion of the investigator 4. subjects able and willing to give written (signed and dated) informed consent to participate in the study exclusion criteria: 1. participation in another clinical trial other than in 11 004 and receipt of an investigational medication other than that administered in the context of in 11 004 within 28 days prior to the planned start of treatment 2. previous or planned neurosurgical or duodopa treatment for parkinson's disease (e.g., procedures including ablation or deep brain stimulation) 3. non-selective monoamine oxidase (mao) inhibitors within 28 days prior to baseline visit or planned administration during study participation 4. if, in the opinion of the investigator, subject should not participate in the study 5. women who are pregnant or nursing. women of childbearing potential who are not willing to use a medically acceptable method of contraception.

Keywords: parkinson's disease fluctuating parkinson's disease carbidopa levodopa accordion
a study of neratinib plus capecitabine versus lapatinib plus capecitabine in patients with her2+ metastatic breast cancer who have received two or more prior her2 directed regimens in the metastatic setting

Conditions: HER2+ Metastatic Breast Cancer (MBC)

Summary: this is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in her2+ mbc patients who have received two or more prior her2 directed regimens in the metastatic setting.

this is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in her2+ mbc patients who have received two or more prior her2 directed regimens in the metastatic setting. patients will be randomized in a 1:1 ratio to one of the following treatment arms: * arm a: neratinib (240 mg once daily) + capecitabine (1500 mg/m\^2 daily, 750 mg/m\^2 twice daily \[bid\]) * arm b: lapatinib (1250 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 bid) patients will receive either neratinib plus capecitabine combination or lapatinib plus capecitabine combination until the occurrence of death, disease progression, unacceptable toxicity, or other specified withdrawal criterion.

Eligibility criteria:
inclusion criteria: * aged ≥18 years at signing of informed consent. * histologically confirmed mbc, current stage iv. * documented her2 overexpression or gene-amplified tumor immunohistochemistry 3+ or 2+, with confirmatory fluorescence in situ hybridization (fish) +. * prior treatment with at least two (2) her2-directed regimens for metastatic breast cancer. exclusion criteria: * received previous therapy with capecitabine, neratinib, lapatinib, or any other her2 directed tyrosine kinase inhibitor. note: there are additional inclusion and exclusion criteria. the study center will determine if you meet all of the criteria.

Keywords: neratinib nerlynx
pulmonary disorders during exercise in patients with obstructive sleep apnea

Conditions: Sleep Apnea, Obstructive; Asthma, Exercise-Induced

Summary: purposes: 1. to investigate whether patients with severe obstructive sleep apnea syndrome (osas) are at higher risk for exercised-induced bronchoconstriction (eib) due to baseline airway inflammation compared with age, gender, and body mass index (bmi)-matched controls. 2. to investigate the effect of 3-month continuous positive airway pressure (cpap) therapy on eib for patients with severe osas.

obstructive sleep apnea syndrome (osas) is characterized by repeated episodes of upper airway obstruction during sleep. recent studies have found evidence of airway inflammation in patients with osas. individuals with chronic airway inflammation are at higher risk for exercise-induced bronchoconstriction (eib). we hypothesized patients with osas are at higher risk for eib due to baseline airway inflammation. continuous positive airway pressure (cpap) is a known standard treatment for osas, thus the second aim of the study will be investigating the effect of 3-month cpap therapy on eib for patients with osas. twenty severe osas patients and 20 control individuals matched for age, gender, and body mass index (bmi) will be recruited. all participants will come to the laboratory on 2 separate days (5\~14 days interval). on the 1st visit, baseline pulmonary function test (pft) and airway inflammation assess by induced sputum will be performed. on the 2nd visit, an exercise challenge test will be performed using standard testing protocol and post-exercise forced expiratory volume in one second (fev1) will be measured at 2.5, 5, 10, 15,20, and 30 minutes. for patients with severe osas, all measurements will be repeated after 3-month cpap therapy.

Eligibility criteria:
inclusion criteria: 1. age ranged 18-65 y/o 2. severe osa (ahi≧30/hr) 3. bmi\<35 kg/m2 exclusion criteria: 1. clinical asthma 2. chronic lung disease (fev1\<70% predicted or fev1/fvc\<70%) 3. exercise contraindication: * stroke or heart attack in last 3 months * major cardiovascular disease * unstable angina * unable to perform cycle ergometry due to musculoskeletal problems 4. respiratory tract infection in the past 2 weeks 5. inability to perform acceptable-quality spirometry 6. refuse to participate

Keywords: obstructive sleep apnea airway inflammation exercise-induced bronchoconstriction continuous positive airway pressure
analysis of clinical application of china's first batch of tyrx absorbable antibacterial envelope

Conditions: CIED Infection; TYRX Absorbable Antibacterial Envelope

Summary: this study is the first to use tyrx domesticly, reporting and summarizing its usage to validate its real-world effectiveness in cied infection prevention.

this study is the first to use tyrx domesticly, reporting and summarizing its usage to validate its real-world effectiveness in cied infection prevention.

Eligibility criteria:
inclusion criteria: * all patients who received the tyrx absorbable antimicrobial envelopes at our hospital from december 2023 to september 2024 exclusion criteria: * allergies to the envelope materials or antimicrobial drugs (minocycline and other tetracyclines, rifampin) * existing infections at the cied implantation site * pregnant or breastfeeding women * children and adolescents
a study in participants with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the primary purpose of this study is to help answer if ly2127399 is safe and effective in the treatment of rheumatoid arthritis in participants with an inadequate response to one or more tumor necrosis factor-alpha (tnf-α) inhibitors. this study is comprised of 2 periods: period 1: 24-week blinded treatment period 2: 48-week post-treatment follow-up


Eligibility criteria:
inclusion criteria: * diagnosis of ra of more than 6 months and less than 15 years * at least 8 tender and swollen joints * an abnormally high c-reactive protein (crp) level or erythrocyte sedimentation rate (esr) * positive for rheumatoid factor (rf) or anti-cyclic citrullinated peptide (ccp) antibody * previously treated with biologic tnf-α inhibitor therapy (infliximab, certolizumab, golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy or intolerance * regular use of at least 1 conventional disease-modifying anti-rheumatic drug (dmard), with a stable dose for at least 8 weeks prior to study start * woman must not be pregnant, breastfeeding, or become pregnant during the study exclusion criteria: * use of unstable doses of non-steroidal anti-inflammatory drugs (nsaids) in the past 6 weeks * steroid injection or intravenous (iv) infusion in the last 6 weeks * use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks * history of a serious reaction to other biological dmards * use of an oral calcineurin inhibitor (for example, cyclosporin or tacrolimus) in the last 8 weeks * surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study * active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except ra * cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years * received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines) * hepatitis or human immunodeficiency virus (hiv) * a serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months * symptoms of herpes zoster or herpes simplex within the last month * active or latent tuberculosis (tb) * current symptoms of a serious disorder or illness * use of an investigational drug within the last month

Keywords: rheumatoid arthritis
nanoparticulate versus micronized steroids delivery for transdermal hormone replacement therapy

Conditions: Menopausal Syndrome

Summary: the study aims to asses the effects of micronized (mic) and nanoparticulate (nano) transdermal hormone therapy (tht) on blood pressure, ultra-sensitive c-reactive protein (crp), and cardiovascular risk factors in postmenopausal women.

in this open label study, 27 postmenopausal women, with no clinical evidence of cardiovascular disease, were randomly divided in two groups. during 12 weeks, 15 patients received on the left forearm micronized (mic) tht (micronized 17β-estradiol 2.5 mg/day + progesterone 100 mg/day). and 14 patients received a nanoparticulate (nano) tht (nanoparticulate 17β-estradiol 2.5 mg/day + progesterone 100mg/day). after 12 weeks of treatment patients were evaluated. baseline and post-tht measures were determined: insulin, body mass index, waist circumference, blood pressure, crp-stratified levels, total testosterone, tsh and fsh levels.

Eligibility criteria:
inclusion criteria: * a body mass index between 18 and 27 kg/m2; * sex live complaints; * no evidence of cardiovascular disease; * general good health based on history and physical examination. exclusion criteria: * a past history of neurological disorder; * had received pharmacotherapy for cardiovascular disease before screening * taking medication known to interfere with steroids; * recent psychiatric or systemic illness; * uncontrolled hypertension (blood pressure\>160/95mmhg), * unstable cardiovascular disease; * genital bleeding; * use of psychoactive medications, * alcohol excess consumption or any other drug abuse;
infasurf®(calfactant) aerosol for infants with bronchiolitis-aero-04

Conditions: Bronchiolitis

Summary: delivery of aerosolized infasurf to bronchiolitis patients with who are not on assisted ventilation can provide sufficient delivery of infasurf to small airways to improve ventilation and thereby shorten the duration of the respiratory illness.

this pilot clinical trial will compare "usual care" to aerosolized infasurf. the study objective is to determine 1. do bronchiolitis patients tolerate aerosolized infasurf? 2. does aerosolized infasurf induce an improvement in respiration? 3. if it does how large a dose is required to observe a positive effect? 4. is the positive effect transient, if so what is the range of duration of the effect? 5. does retreatment also result and a positive response? 6. does aerosolized infasurf result in more rapid sustained improvement? is superior to.

Eligibility criteria:
inclusion criteria: 1. infant ≤ 4 months of age admitted to the picu with the clinical diagnosis of bronchiolitis 2. severe illness as reflected by a bronchiolitis score ≥ 4 and requiring high flow nasal cannula or continuous positive airway pressure for respiratory support 3. within 4 hours of picu admission. exclusion criteria: 1. need for non-invasive bipap or invasive ventilation 2. significant co-morbidities 1. chronic lung disease (evidenced by supplemental oxygen, home ventilation, or chronic diuretic therapy for cld) 2. unrepaired congenital heart disease 3. immune compromise 4. neuromuscular weakness 3. tracheostomy 4. influenza as the etiologic agent of bronchiolitis 5. inability to stabilize the infant to a bronchiolitis score \< 8
study of neurological damage from coronavirus disease (covid-19)

Conditions: COVID-19

Summary: the objective of this study is to support the exploration of the neuro-covid-19 database and in particular to carry out the post-treatments necessary to derive quantitative information on the characterization of the lesion load, in particular with regard to of the vascular tree


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * covid + patient presenting with neurological symptoms leading to an mri. * patient taken care of in one of the care centers associated with this research * patient not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. exclusion criteria: * patient who expressed his opposition to participating in the study * covid patient not having neurological symptoms or not having received an mri * patient under guardianship or guardianship * patient under legal protection

Keywords: covid-19 sars-cov-2 central nervous system headache loss of smell coma
pulsar - a prospective study to evaluate the utility of low doses of the statins atorvastatin and rosuvastatin.

Conditions: Hypercholesterolaemia

Summary: to compare reduction of ldl-c and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment


Eligibility criteria:
inclusion criteria: * male or female 18 or over. * a history of chd or clinical evidence of atherosclerosis (diabetic or non-diabetic) or a chd risk equivalent (10-year risk score \> 20% for chd as described in ncep atp iii guidelines1. exclusion criteria: * history of statin induced myopathy, or serious hypersensitivity reaction to other hmg-coa reductase inhibitors (statins), including rosuvastatin * pregnancy * history of homozygous familial hypercholesterolaemia.
comparison of quality of life after discharge of the mild and moderate covid-19 patients with or without herbal medicine

Conditions: COVID-19 Pandemic; Quality of Life

Summary: the purpose of this study is to see how the acute stage covid-19 treatments by use of herbal medicine (shen cao gan jiang tang) affect quality of life and symptoms at 3 months after hospital discharge.

according to the theory of traditional medicine, the patient will suffer damage to qi and fluid in the acute phase and lead to damaged yin and qi in the post covid-19 period. the shen cao gan jiang tang has the effect of enhance the protective qi, generating fluid, is applied to treat the mild and moderate covid-19 in the acute phase in some hospitals in ho chi minh city, viet nam. the hypothesis is that with the use of the shen cao gan jiang tang, the qi and yin will reduce the damage, so that the patient has a better quality of life and fewer post covid-19 symptoms compared with the standard of care group

Eligibility criteria:
inclusion criteria: * patients able to understand and fill out a questionnaire * from full 18 to 64 years old; * patients with the mild and moderate covid-19 who used shen cao gan jiang tang in the acute phase for intervention group. * participants enrolled in protocol nct05055427. * voluntarily consented to participate in the study exclusion criteria: * patient who are not able to complete 100% of the questionnaire criteria for stopping the study * the patient cannot be contacted after 04 calls, each call is at least 06 hours apart on the survey days. * the patient does not want to continue participating in the study.
a study of aripiprazole in patients with bipolar i disorder with a major depressive episode

Conditions: Bipolar Disorder

Summary: the purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.


Eligibility criteria:
inclusion criteria: * outpatients * must sign informed consent prior to protocol-related procedures exclusion criteria: * women who are pregnant, trying to become pregnant, or nursing * significant risk of committing suicide * any serious unstable medical conditions

Keywords: bipolar i disorder with major depressive episode
identification of carotid vasa vasorum and correlation with acute coronary events

Conditions: Coronary Artery Disease

Summary: adventitial vasa vasorum (vv) as well as intraplaque microvessels are known to be associated with atherosclerotic plaque vulnerability. contrast-enhanced ultrasound has been validated as a technique to measure the density of vv. previous studies have demonstrated a relationship between identification of vv and relationship to vascular events such as stroke and myocardial infarction. no previous study has reported the utilization of contrast-enhanced ultrasound identification of vv in the carotid bed as a means of identifying patients at high risk for acute coronary events. aims: in this study, the investigators will aim to identify vv and intraplaque microvessels along with carotid intima media thickness (cimt), a known marker for acute coronary events. the investigators will attempt to measure the correlation of vv with acute coronary events independent of traditional cardiovascular disease (cvd) risk factors and cimt. methods: 90 volunteers (30 low risk patients, 30 patients with established coronary artery disease (cad), and 30 patients with recent acute coronary syndrome (acs)) will be enrolled. all patients will undergo contrast-enhanced ultrasound imaging of their carotid arteries and measurement of cimt while obtaining baseline histories and assessment of traditional risk factors for coronary artery disease. vv density and cimt will be measured in all patients. statistical differences in vv among the three groups will be assessed and analyses will be made to attempt to identify if vv in the carotid bed is an independent predictor of acute coronary events after controlling for cimt and traditional risk factors. study population: the study population will reflect the patient population of upmc. no individual will be excluded on the basis of race, gender, or ethnicity.


Eligibility criteria:
inclusion criteria: * individuals referred for elective left heart catheterization in the past three months or individuals who have undergone recent left heart catheterization for acute coronary syndrome in the past 3 months exclusion criteria: * inability to provided informed consent * pregnancy or of lack confirmed urine or serum b-hcg testing in pre-menopausal women under the age of 50 * known allergy to definity (registered trademark) * contraindications to definity including permanent or transient right to left or bidirectional cardiac shunts, allergy to perflutren, severe pulmonary hypertension * known cocaine abuse within the past year * history of heart transplantation